Evaluación de Tecnologías Sanitarias

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis-C Virus Infection in Venezuela

S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,C. A. Obando and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS-C VIRUS INFECTION IN VENEZUELA. Value in Health. 2013;16(7).

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis-C Virus Infection in Venezuela Ver más »

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Chile

S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,D. O. Reisberg,A. S. Ried,J. Poniachik,J. R. B. Barril and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN CHILE. Value in Health. 2013;16(7).

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Chile Ver más »

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Colombia

S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,V. Idrovo,J. P. Ortiz,M. Tapias,J. Obregon,J. G. Ariza and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN COLOMBIA. Value in Health. 2013;16(7).

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Colombia Ver más »

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Argentina

S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,F. Bessone,H. Fainboim,A. Gadano,O. Galdame,C. Vujacich and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA. Value in Health. 2013;16(7).

Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Argentina Ver más »

Cost-Effectiveness Analysis Of A Randomized Trial Of An Mhealth Intervention To Improve Cardiometabolic Profile In Prehypertensive Subjects From Low-Resource Urban Settings In Latin America

R. Augustovski,A. Palacios,A. Beratarrechea,F. Diez-Canseco,V. Irazola,M. Ramirez-Zea,A. Pichon-Riyiere and A. Rubinstein. COST-EFFECTIVENESS ANALYSIS OF A RANDOMIZED TRIAL OF AN MHEALTH INTERVENTION TO IMPROVE CARDIOMETABOLIC PROFILE IN PREHYPERTENSIVE SUBJECTS FROM LOW-RESOURCE URBAN SETTINGS IN LATIN AMERICA. Value in Health. 2017;20(9).

Cost-Effectiveness Analysis Of A Randomized Trial Of An Mhealth Intervention To Improve Cardiometabolic Profile In Prehypertensive Subjects From Low-Resource Urban Settings In Latin America Ver más »

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

L. Schluckebier,R. Caetano,O. U. Garay,G. T. Montenegro,M. Custodio,V. Aran and C. Gil Ferreira. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):10.1186/s12885-020-07240-2.

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients Ver más »

Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

D. Husereau,M. Drummond,F. Augustovski,E. de Bekker-Grob,A. H. Briggs,C. Carswell,L. Caulley,N. Chaiyakunapruk,D. Greenberg,E. Loder,J. Mauskopf,C. D. Mullins,S. Petrou,R. F. Pwu and S. Staniszewska. Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Appl Health Econ Health Policy. 2022;20(5):10.1007/s40258-022-00743-y.

Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations Ver más »

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

D. Husereau,M. Drummond,S. Petrou,C. Carswell,D. Moher,D. Greenberg,F. Augustovski,A. H. Briggs,J. Mauskopf,E. Loder and I. H. E. E. Publica. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health. 2013;16(2):10.1016/j.jval.2013.02.002.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force Ver más »

Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome

M. Donato,F. C. Carini,M. J. Meschini,I. L. Saubidet,A. Goldberg,M. G. Sarubio,D. Olmos and R. Reina. Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome. Rev Bras Ter Intensiva. 2021;33(1):10.5935/0103-507x.20210005.

Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome Ver más »